Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
暂无分享,去创建一个
Andrzej Członkowski | George B Stefano | A. Członkowska | I. Kurkowska-Jastrzębska | G. Stefano | Anna Członkowska | A. Członkowski | Iwona Kurkowska-Jastrzebska | Doris Peter | D. Peter
[1] F. Cunha,et al. Interleukin‐8 as a mediator of sympathetic pain , 1991, British journal of pharmacology.
[2] I. Mefford,et al. Cytokine-induced activation of the neuroendocrine stress axis persists in endotoxin-tolerant mice , 1991, Brain Research.
[3] G. Fricchione,et al. The immune-neuro-link and the macrophage: Postcardiotomy delirium, HIV-associated dementia and psychiatry , 1994, Progress in Neurobiology.
[4] Jellinger Ka. Neurodegenerative disorders with extrapyramidal features--a neuropathological overview. , 1995 .
[5] C. Brosnan,et al. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. , 1991, Journal of Immunology.
[6] M. Ebadi,et al. Ubiquinone (Coenzyme Q10) and Mitochondria in Oxidative Stress of Parkinson’s Disease , 2001, Neurosignals.
[7] T. Bilfinger,et al. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. , 1998, Journal of cardiovascular pharmacology.
[8] S. Mariotto,et al. Inhibition by sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils , 1995, British journal of pharmacology.
[9] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[10] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[11] P. Mander,et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.
[12] H. Nishino,et al. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons , 2001, Brain Research.
[13] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[14] S. Imaoka,et al. Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. , 1999, Journal of hepatology.
[15] A. Członkowska,et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.
[16] A. Członkowska,et al. [3H]Spiperone binding to lymphocyte in extrapyramidal disease and in aging , 1987, Brain, Behavior, and Immunity.
[17] Irun R. Cohen,et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.
[18] J. Stamler,et al. Posttranslational Modification of Glyceraldehyde-3-phosphate Dehydrogenase by S-Nitrosylation and Subsequent NADH Attachment (*) , 1996, The Journal of Biological Chemistry.
[19] P. Kubes,et al. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. , 1994, Circulation research.
[20] A. Minajeva,et al. Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase , 1999, FEBS letters.
[21] Joseph E Parisi,et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.
[22] M. Blobner,et al. Inhibition of nitric oxide synthesis improves detoxication in inflammatory liver dysfunction in vivo. , 1997, The American journal of physiology.
[23] P. Kubes,et al. Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[24] G. Chrousos,et al. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. , 1992, JAMA.
[25] M. Marletta,et al. Guanylate cyclase and the .NO/cGMP signaling pathway. , 1999, Biochimica et biophysica acta.
[26] B. Kalyanaraman,et al. Nitric oxide and lipid peroxidation. , 1999, Biochimica et biophysica acta.
[27] B. Liu,et al. Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.
[28] C. Marsden,et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.
[29] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[30] S. Moncada,et al. The Discovery of Nitric Oxide as the Endogenous Nitrovasodilator , 1988, Hypertension.
[31] A. Rajput,et al. Is levodopa toxic to human substantia nigra? , 1997, Movement disorders : official journal of the Movement Disorder Society.
[32] P. Kubes,et al. Nitric oxide syni hesis inhibition induces leukocyte adhesion via superoxid and mast cells , 2004 .
[33] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[34] G. Stefano,et al. HIV gp120 associated neurological deficits: a potential role for nitric oxide and other signal molecules , 1993 .
[35] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[36] G. Brown,et al. Reversible binding and inhibition of catalase by nitric oxide. , 1995, European journal of biochemistry.
[37] T. Bergman,et al. S-thiolation of human endothelial cell glyceraldehyde-3-phosphate dehydrogenase after hydrogen peroxide treatment. , 1994, European journal of biochemistry.
[38] I. Mizuta,et al. Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease , 2000, Neuroscience Letters.
[39] D. Heistad,et al. Regulation of the cerebral circulation: role of endothelium and potassium channels. , 1998, Physiological reviews.
[40] S. Snyder,et al. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Schapira. Neuroprotection and dopamine agonists , 2002, Neurology.
[42] S. Mohand-Said,et al. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.
[43] Y. Agid,et al. Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.
[44] T. Bilfinger,et al. Human monocyte adhesion is modulated by endothelin B receptor-coupled nitric oxide release. , 1997, Journal of immunology.
[45] G. Burnstock,et al. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? , 1996, Biochemical and biophysical research communications.
[46] G. Stefano,et al. Rebound from Nitric Oxide Inhibition Triggers Enhanced Monocyte Activation and Chemotaxis1 , 2000, The Journal of Immunology.
[47] F. Hefti,et al. The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth FACTOR-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture , 1993, Neuroscience.
[48] A. Członkowska,et al. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. , 2002, International immunopharmacology.
[49] H. Neumann,et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. , 2001, The American journal of pathology.
[50] P. Lapchak. A role for interleukin‐2 in the regulation of striatal dopaminergic function , 1992, Neuroreport.
[51] F. Murad. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? , 1998, Recent progress in hormone research.
[52] C. Elger,et al. Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis , 2002, Annals of neurology.
[53] G. Fricchione,et al. Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. , 1996, Journal of immunology.
[54] J S Beckman,et al. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.
[55] H. Przuntek,et al. Selegiline as immunostimulant--a novel mechanism of action? , 1998, Journal of neural transmission. Supplementum.
[56] T. Hintze,et al. Nitric oxide. An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. , 1995, Circulation.
[57] B. Brüne,et al. Nitric Oxide-induced S-Glutathionylation and Inactivation of Glyceraldehyde-3-phosphate Dehydrogenase* , 1999, The Journal of Biological Chemistry.
[58] W. Hickey,et al. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. , 1988, Science.
[59] A. Członkowska,et al. The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.
[60] X. Xu,et al. Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. , 1998, Circulation research.
[61] M. Graeber,et al. Parkinson disease: analysis of mitochondrial DNA in monozygotic twins , 2000, Neurogenetics.
[62] T. Bilfinger,et al. Basal nitric oxide limits immune, nervous and cardiovascular excitation: human endothelia express a mu opiate receptor , 2000, Progress in Neurobiology.
[63] K. Tieu,et al. Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes , 2001, Neuroscience.
[64] S. Moncada,et al. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide , 1994, FEBS letters.
[65] M. Graeber,et al. Identity of ED2‐positive perivascular cells in rat brain , 1989, Journal of neuroscience research.
[66] G. Zhao,et al. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. , 1994, Circulation research.
[67] L. Deecke,et al. Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies , 2001, Experimental Gerontology.
[68] N. Rothwell,et al. Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[69] M. Masana,et al. Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[70] D. Palazzolo,et al. Interleukin-1 stimulates catecholamine release from the hypothalamus. , 1990, Life sciences.
[71] G. Defazio,et al. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture , 1994, Brain Research.
[72] V. Perry,et al. Macrophages and the nervous system. , 1994, International review of cytology.
[73] R. Kaji,et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease , 2001, Neuroscience Letters.
[74] P. Mcgeer,et al. Inflammation in Parkinson's disease. , 2001, Advances in neurology.
[75] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[76] G. Fricchione,et al. Opioid and Opiate Immunoregulatory Processes. , 2017, Critical reviews in immunology.
[77] A. Fontana,et al. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. , 1982, Journal of immunology.
[78] J. Balligand,et al. Reversible S-nitrosation of creatine kinase by nitric oxide in adult rat ventricular myocytes. , 1998, Journal of molecular and cellular cardiology.
[79] I. Ziv,et al. Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? , 1998, Movement disorders : official journal of the Movement Disorder Society.
[80] D. Wink,et al. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.
[81] H. Magazine,et al. Thrombin receptor activation inhibits monocyte spreading by induction of ET(B) receptor-coupled nitric oxide release. , 1998, Journal of immunology.
[82] A. Członkowska,et al. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. , 1999, Acta neurobiologiae experimentalis.
[83] I. Ziv,et al. Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.
[84] T. Dawson,et al. Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[85] H. Hatanaka,et al. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures , 1991, Neuroscience.
[86] J. C. Torre,et al. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide , 2000, Brain Research Reviews.
[87] A. Dahlström,et al. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. , 1990, Journal of neural transmission. Supplementum.
[88] P. Riederer,et al. Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .
[89] B. Brüne,et al. Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. , 1992, The Journal of biological chemistry.
[90] G. Stefano,et al. Tonal nitric oxide and health: anti-bacterial and -viral actions and implications for HIV. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[91] H. Kimura,et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.
[92] Wenjie Xie,et al. Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.
[93] D. Lefer,et al. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. , 1998, Free radical biology & medicine.
[94] H. Neumann,et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.
[95] A. Dunn. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.
[96] A. Hofman,et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.
[97] O. Abramsky,et al. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. , 1978, Perspectives in biology and medicine.
[98] E. Agranov,et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury , 2000, The Lancet.
[99] S. Gordon,et al. Biology of the Macrophage , 1986, Journal of Cell Science.
[100] C. Richter,et al. Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. , 1994, Biochemical and biophysical research communications.
[101] T. Bilfinger,et al. Effect of prolonged exposure to morphine on responsiveness of human and invertebrate immunocytes to stimulatory molecules , 1995, Journal of Neuroimmunology.
[102] T. Elizan,et al. Search for viral particles and virus‐specific products in idiopathic Parkinson disease brain material , 1979, Annals of neurology.
[103] T. Bilfinger,et al. Antagonism of LPS and IFN-gamma induced iNOS expression in human atrial endothelia by morphine, anandamide, and estrogen. , 2000, Acta pharmacologica Sinica.
[104] L. Waite,et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.
[105] M. Schwartz,et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. , 2000, Journal of autoimmunity.
[106] S. Mariotto,et al. Bacterial Lipopolysaccharide Plus Interferon-γ Elicit a Very Fast Inhibition of a Ca2+-dependent Nitric-oxide Synthase Activity in Human Astrocytoma Cells* , 1997, The Journal of Biological Chemistry.
[107] P. Carvey,et al. A Clonal Line of Mesencephalic Progenitor Cells Converted to Dopamine Neurons by Hematopoietic Cytokines: A Source of Cells for Transplantation in Parkinson's Disease , 2001, Experimental Neurology.
[108] T. Bilfinger,et al. Macrophage behavior associated with acute and chronic exposure to HIV GP120, morphine and anandamide: endothelial implications. , 1998, International journal of cardiology.
[109] T. Yamada,et al. Viral etiology for Parkinson's disease--a possible role of influenza A virus infection. , 1999, Japanese journal of infectious diseases.
[110] D. Salvemini. Regulation of cyclooxygenase enzymes by nitric oxide , 1997, Cellular and Molecular Life Sciences CMLS.
[111] S. Mariotto,et al. Rapid Inactivation of NOS-I by Lipopolysaccharide Plus Interferon-γ-induced Tyrosine Phosphorylation* , 1999, The Journal of Biological Chemistry.
[112] P. Kubes,et al. Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. , 1993, Circulation research.
[113] S. Ambrosio,et al. Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism , 2001, Journal of Neuroimmunology.
[114] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[115] P. Mcgeer,et al. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.
[116] V. Kostulas,et al. Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood , 1994, Acta neurologica Scandinavica.
[117] K. Kristensson. Potential role of viruses in neurodegeneration , 1992, Molecular and chemical neuropathology.
[118] T. Bilfinger,et al. Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. , 1998, Journal of cardiovascular pharmacology.
[119] W. Hickey,et al. Leukocyte traffic in the central nervous system: the participants and their roles. , 1999, Seminars in immunology.
[120] S. Kohbata,et al. L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice , 1991, Infection and immunity.
[121] Y. Ganor,et al. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates β1 integrin function , 2001, European journal of immunology.
[122] T. Olsson,et al. γδ + T cells are increased in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[123] E. Clarkson,et al. GDNF reduces apoptosis in dopaminergic neurons in vitro , 1995, Neuroreport.
[124] T. Esch,et al. Proinflammation: a common denominator or initiator of different pathophysiological disease processes. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[125] H. Magazine. Detection of endothelial cell-derived nitric oxide: current trends and future directions. , 1995, Advances in neuroimmunology.
[126] V. Perry,et al. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain , 1985, Neuroscience.
[127] H. Lassmann,et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis , 2000, Journal of Neuroimmunology.
[128] A. Członkowska,et al. Immunological changes in the MPTP-induced Parkinson's disease mouse model , 1993, Journal of Neuroimmunology.
[129] M. Vila,et al. The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.
[130] C. Cooper,et al. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase , 1994, FEBS letters.
[131] J P Cooke,et al. Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.
[132] I. Strömberg,et al. Guidance of dopaminergic neuritic growth by immature astrocytes in organotypic cultures of rat fetal ventral mesencephalon , 2002, The Journal of comparative neurology.
[133] G. Stefano,et al. Tonal nitric oxide and health--a free radical and a scavenger of free radicals. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[134] M. Grisham,et al. Effect of nitric oxide on hemoprotein-catalyzed oxidative reactions. , 1998, Nitric oxide : biology and chemistry.
[135] S. Murphy,et al. Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. , 1997, The Biochemical journal.
[136] A. Barbeau,et al. Environmental and genetic factors in the etiology of Parkinson's disease. , 1987, Advances in neurology.
[137] P. Lapchak,et al. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: Selective effects on specific interleukins and interleukin receptors , 1994, Neuroscience.
[138] A. Kaszniak,et al. Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.
[139] T. Kuroki,et al. Role of glutathione and nitric oxide in the energy metabolism of rat liver mitochondria , 1997, FEBS letters.
[140] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[141] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[142] J. Hibbs,et al. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.
[143] M. J. Winn,et al. Canine hindlimb blood flow and O2 uptake after inhibition of EDRF/NO synthesis. , 1994, Journal of applied physiology.
[144] G. Stefano. Autoimmunovascular regulation: morphine and ancondamide and ancondamide stimulated nitric oxide release , 1998, Journal of Neuroimmunology.
[145] G. Brown,et al. Nitric oxide and mitochondrial respiration. , 1999, Biochimica et biophysica acta.
[146] E. M. Smith,et al. HIV gp120 alteration of DAMA and IL-1α induced chemotaxic responses in human and invertebrate immunocytes , 1993, Journal of Neuroimmunology.
[147] L. Mucke,et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[148] S. Murphy,et al. Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. , 1994, Biochemical and biophysical research communications.
[149] A. Członkowska,et al. Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[150] M. Marletta. Nitric oxide: biosynthesis and biological significance. , 1989, Trends in biochemical sciences.
[151] P. Carvey,et al. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .
[152] G. Stefano,et al. Cyclic nitric oxide release by human granulocytes, and invertebrate ganglia and immunocytes: nano-technological enhancement of amperometric nitric oxide determination. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[153] M. Graeber,et al. Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease , 1998, Neurogenetics.
[154] M. Shichiri,et al. NO Inhibits Cytokine-Induced iNOS Expression and NF-κB Activation by Interfering With Phosphorylation and Degradation of IκB-α , 1998 .
[155] R. Bache,et al. ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. , 1998, Circulation research.
[156] S. Milstien,et al. Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone , 1997, Progress in Neurobiology.
[157] A. Członkowska,et al. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[158] E. Hansson,et al. Signaling and gene expression in the neuron–glia unit during brain function and dysfunction: Holger Hydén in memoriam , 2001, Neurochemistry International.
[159] A. Członkowska,et al. The immunological status in Parkinson's disease. , 1991, Medical laboratory sciences.
[160] P. Södersten,et al. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.
[161] C. Caldarera,et al. Induction of Nitric Oxide Synthase mRNA Expression , 1995, The Journal of Biological Chemistry.
[162] Solomon H. Snyder,et al. Nitric oxide, a novel neuronal messenger , 1992, Neuron.
[163] T. Billiar,et al. Nitric oxide down-regulates hepatocyte-inducible nitric oxide synthase gene expression. , 1997, Archives of surgery.
[164] K. Utsumi,et al. Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. , 1995, Archives of biochemistry and biophysics.
[165] J. Kanner,et al. Nitric oxide as an antioxidant. , 1991, Archives of biochemistry and biophysics.
[166] P. Kubes,et al. Nitric oxide modulates microvascular permeability. , 1992, The American journal of physiology.